Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Oktober 2010 10:30 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Present at the Oppenheimer 21st Annual Healthcare Conference

CAMBRIDGE, Mass., Oct. 26, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
25. Oktober 2010 11:30 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals Awarded Second U.S. Patent for Evaluating Mixtures of Low Molecular Weight Heparins by Chain Profiles or Chain Mapping

CAMBRIDGE, Mass., Oct. 25, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
19. Oktober 2010 13:06 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Present at the Newsmakers in the Biotech Industry Conference

CAMBRIDGE, Mass., Oct. 19, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
17. September 2010 11:30 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Present at the UBS Global Life Sciences Conference

CAMBRIDGE, Mass., Sept. 17, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
13. September 2010 09:27 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals Awarded U.S. Patent for Evaluating Mixtures of Low Molecular Weight Heparins by Chain Profiles or Chain Mapping

CAMBRIDGE, Mass., Sept. 13, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
10. September 2010 16:05 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Change to Board of Directors

CAMBRIDGE, Mass., Sept. 10, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
08. September 2010 14:45 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
26. August 2010 08:00 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals Provides Litigation Update

CAMBRIDGE, Mass., Aug. 26, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
09. August 2010 14:00 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Present at the Canaccord 30th Annual Global Growth Conference and the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference

CAMBRIDGE, Mass., Aug. 9, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
02. August 2010 08:06 ET | Quelle: Momenta Pharmaceuticals

Momenta Pharmaceuticals Reports Financial Results for the Second Quarter of 2010

CAMBRIDGE, Mass., Aug. 2, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...

Vorherige Seite

Nächste Seite